Collegium Pharmaceutical (NASDAQ:COLL) Rating Increased to Strong-Buy at StockNews.com

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Tuesday.

A number of other research analysts have also recently weighed in on COLL. Jefferies Financial Group reissued a “hold” rating and set a $37.00 price objective (up from $30.00) on shares of Collegium Pharmaceutical in a research note on Thursday, January 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $40.00 price objective on shares of Collegium Pharmaceutical in a research note on Thursday, April 11th. Truist Financial boosted their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. Finally, Piper Sandler reiterated an “overweight” rating and set a $39.00 price target (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $39.00.

Collegium Pharmaceutical Stock Performance

COLL opened at $35.48 on Tuesday. Collegium Pharmaceutical has a 1-year low of $20.83 and a 1-year high of $40.95. The stock has a market cap of $1.16 billion, a P/E ratio of 30.07 and a beta of 1.03. The stock’s 50 day simple moving average is $37.02 and its 200 day simple moving average is $31.14. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.17 and a quick ratio of 1.10.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The business had revenue of $149.75 million during the quarter, compared to analysts’ expectations of $147.66 million. As a group, equities analysts anticipate that Collegium Pharmaceutical will post 5.63 EPS for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. grew its holdings in Collegium Pharmaceutical by 68.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after purchasing an additional 883,380 shares during the period. Natixis Advisors L.P. grew its stake in shares of Collegium Pharmaceutical by 152.9% during the 3rd quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company’s stock valued at $1,215,000 after buying an additional 32,865 shares during the period. Loomis Sayles & Co. L P increased its holdings in shares of Collegium Pharmaceutical by 32.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company’s stock worth $6,116,000 after buying an additional 67,439 shares during the last quarter. Barclays PLC increased its holdings in shares of Collegium Pharmaceutical by 16.9% during the 3rd quarter. Barclays PLC now owns 39,593 shares of the specialty pharmaceutical company’s stock worth $886,000 after buying an additional 5,713 shares during the last quarter. Finally, Everence Capital Management Inc. purchased a new position in shares of Collegium Pharmaceutical in the 4th quarter worth $302,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.